Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Amita PatnaikTimothy Anthony YapHyun Cheol ChungMaria J de Miguel LukenYung-Jue BangChia-Chi LinWu-Chou SuAntoine ItalianoKay Hoong ChowAnna M SzpurkaDanni YuYumin ZhaoMichelle CarlsenShelly SchmidtBurkhard VangerowLeena GandhiXiaojian XuJohanna BendellPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
LY3300054 was well tolerated without unexpected safety concerns when administered alone or concurrently with ramucirumab, abemaciclib, or merestinib. Lead-in abemaciclib before combining with LY3300054 was not feasible due to hepatotoxicity. Durable clinical benefits were seen in all regimens.